Cargando…

Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor

BACKGROUND/AIMS: Individuals being treated with tumor necrosis factor (TNF)-α inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-α inhibitors. METHODS: Patients with TB detec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Keun Bum, Lee, Eun Young, Im, Jong Pil, Han, Sung Koo, Yim, Jae-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604607/
https://www.ncbi.nlm.nih.gov/pubmed/23525649
http://dx.doi.org/10.3904/kjim.2013.28.2.174
_version_ 1782263768610242560
author Chung, Keun Bum
Lee, Eun Young
Im, Jong Pil
Han, Sung Koo
Yim, Jae-Joon
author_facet Chung, Keun Bum
Lee, Eun Young
Im, Jong Pil
Han, Sung Koo
Yim, Jae-Joon
author_sort Chung, Keun Bum
collection PubMed
description BACKGROUND/AIMS: Individuals being treated with tumor necrosis factor (TNF)-α inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-α inhibitors. METHODS: Patients with TB detected within 12 months of the initiation of TNF-α inhibitor treatment were included, if seen from January 1, 2000 to August 31, 2011. We retrospectively reviewed the clinical records, results of bacteriological examinations, and radiographs of the included patients and the response to anti-TB treatment. RESULTS: We indentified seven cases of TB in 457 patients treated with TNF-α inhibitors during the study period. TB developed a median of 123 days (range, 48 to 331) after the first dose of TNF-α inhibitor. Pulmonary TB, including TB pleuritis, was diagnosed in three patients and extrapulmonary TB in four. Favorable treatment outcomes were achieved in six of seven patients. CONCLUSIONS: Among the TNF-α inhibitor users who contracted TB, extrapulmonary sites were common and the treatment response was satisfactory.
format Online
Article
Text
id pubmed-3604607
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-36046072013-03-22 Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor Chung, Keun Bum Lee, Eun Young Im, Jong Pil Han, Sung Koo Yim, Jae-Joon Korean J Intern Med Original Article BACKGROUND/AIMS: Individuals being treated with tumor necrosis factor (TNF)-α inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-α inhibitors. METHODS: Patients with TB detected within 12 months of the initiation of TNF-α inhibitor treatment were included, if seen from January 1, 2000 to August 31, 2011. We retrospectively reviewed the clinical records, results of bacteriological examinations, and radiographs of the included patients and the response to anti-TB treatment. RESULTS: We indentified seven cases of TB in 457 patients treated with TNF-α inhibitors during the study period. TB developed a median of 123 days (range, 48 to 331) after the first dose of TNF-α inhibitor. Pulmonary TB, including TB pleuritis, was diagnosed in three patients and extrapulmonary TB in four. Favorable treatment outcomes were achieved in six of seven patients. CONCLUSIONS: Among the TNF-α inhibitor users who contracted TB, extrapulmonary sites were common and the treatment response was satisfactory. The Korean Association of Internal Medicine 2013-03 2013-02-27 /pmc/articles/PMC3604607/ /pubmed/23525649 http://dx.doi.org/10.3904/kjim.2013.28.2.174 Text en Copyright © 2013 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Chung, Keun Bum
Lee, Eun Young
Im, Jong Pil
Han, Sung Koo
Yim, Jae-Joon
Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
title Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
title_full Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
title_fullStr Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
title_full_unstemmed Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
title_short Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
title_sort clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604607/
https://www.ncbi.nlm.nih.gov/pubmed/23525649
http://dx.doi.org/10.3904/kjim.2013.28.2.174
work_keys_str_mv AT chungkeunbum clinicalcharacteristicsandtreatmentresponsesofpatientswhodevelopedtuberculosisfollowinguseofatumornecrosisfactorainhibitor
AT leeeunyoung clinicalcharacteristicsandtreatmentresponsesofpatientswhodevelopedtuberculosisfollowinguseofatumornecrosisfactorainhibitor
AT imjongpil clinicalcharacteristicsandtreatmentresponsesofpatientswhodevelopedtuberculosisfollowinguseofatumornecrosisfactorainhibitor
AT hansungkoo clinicalcharacteristicsandtreatmentresponsesofpatientswhodevelopedtuberculosisfollowinguseofatumornecrosisfactorainhibitor
AT yimjaejoon clinicalcharacteristicsandtreatmentresponsesofpatientswhodevelopedtuberculosisfollowinguseofatumornecrosisfactorainhibitor